187 related articles for article (PubMed ID: 32544354)
21. Epigenetic Regulation of the Nitric Oxide Pathway, 17-α Hydroxyprogesterone Caproate, and Recurrent Preterm Birth.
Manuck TA; Smeester L; Martin EM; Tomlinson MS; Smith C; Varner MW; Fry RC
Am J Perinatol; 2018 Jul; 35(8):721-728. PubMed ID: 29241278
[TBL] [Abstract][Full Text] [Related]
22. Recurrent Preterm Birth Reduction by 17-Hydroxyprogesterone Caproate in Dichorionic/Diamniotic Twin Gestation.
Megli C; Combs CA; Venkataramanan R; Lemon L; Caritis SN
Am J Perinatol; 2022 Aug; 39(11):1183-1188. PubMed ID: 33321529
[TBL] [Abstract][Full Text] [Related]
23. A national survey examining obstetrician perspectives on use of 17-alpha hydroxyprogesterone caproate post-US FDA approval.
Rebarber A; Fox N; Klauser CK; Saltzman D; Roman AS
Clin Drug Investig; 2013 Aug; 33(8):571-7. PubMed ID: 23800978
[TBL] [Abstract][Full Text] [Related]
24. A systematic review and meta-analysis of randomized controlled trials comparing 17-alpha-hydroxyprogesterone caproate versus placebo for the prevention of recurrent preterm birth.
Fernandez-Macias R; Martinez-Portilla RJ; Cerrillos L; Figueras F; Palacio M
Int J Gynaecol Obstet; 2019 Nov; 147(2):156-164. PubMed ID: 31402445
[TBL] [Abstract][Full Text] [Related]
25. Addressing a broken drug pipeline for preterm birth: why early preterm birth is an orphan disease.
Baxter C; Crary I; Coler B; Marcell L; Huebner EM; Rutz S; Adams Waldorf KM
Am J Obstet Gynecol; 2023 Dec; 229(6):647-655. PubMed ID: 37516401
[TBL] [Abstract][Full Text] [Related]
26. Quality assessment of compounded 17-hydroxyprogesterone caproate.
Chang J; Zhao Y; Zhao W; Venkataramanan R; Caritis SN;
Am J Obstet Gynecol; 2014 Jan; 210(1):47.e1-7. PubMed ID: 24200163
[TBL] [Abstract][Full Text] [Related]
27. Re-examining the Meis Trial for Evidence of False-Positive Results.
Sibai B; Saade GR; Das AF
Obstet Gynecol; 2020 Sep; 136(3):622-627. PubMed ID: 32769653
[TBL] [Abstract][Full Text] [Related]
28. 17-α hydroxyprogesterone caproate for the prevention of preterm birth.
Gupta S; Roman AS
Womens Health (Lond); 2012 Jan; 8(1):21-30. PubMed ID: 22171770
[TBL] [Abstract][Full Text] [Related]
29. Progesterone therapy for prevention of recurrent spontaneous preterm birth in a minority patient population: a retrospective study.
Mazza GR; Komatsu E; Ponzio M; Bai C; Cortessis VK; Sasso EB
BMC Pregnancy Childbirth; 2024 Apr; 24(1):252. PubMed ID: 38589796
[TBL] [Abstract][Full Text] [Related]
30. Practical considerations with 17-Hydroxyprogesterone caproate for preterm birth prevention: does timing of initiation and compliance matter?
Carter EB; Cahill AG; Olsen MA; Macones GA; Tuuli MG; Stout MJ
J Perinatol; 2019 Sep; 39(9):1182-1189. PubMed ID: 31217529
[TBL] [Abstract][Full Text] [Related]
31. Preterm Birth and 17OHP - Why the FDA Should Not Withdraw Approval.
Greene MF; Klebanoff MA; Harrington D
N Engl J Med; 2020 Dec; 383(24):e130. PubMed ID: 33140924
[No Abstract] [Full Text] [Related]
32. 17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth - A Systematic Review and Meta-analysis Taking into Account the PROLONG Trial.
Kuon RJ; Berger R; Rath W
Geburtshilfe Frauenheilkd; 2021 Jan; 81(1):61-69. PubMed ID: 33487666
[No Abstract] [Full Text] [Related]
33. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
Stringer EM; Vladutiu CJ; Batra P; Stringer JSA; Menard MK
Obstet Gynecol; 2016 Dec; 128(6):1397-1402. PubMed ID: 27824772
[TBL] [Abstract][Full Text] [Related]
34. Progesterone for Prevention of Preterm Birth: Shortcomings and Unintended Consequences of the Orphan Drug Act.
Gee RE; Kuy S; Karas LO
Obstet Gynecol; 2017 Dec; 130(6):1202-1206. PubMed ID: 29112651
[TBL] [Abstract][Full Text] [Related]
35. PROLONG Clinical Study Protocol: Hydroxyprogesterone Caproate to Reduce Recurrent Preterm Birth.
Blackwell SC; Gyamfi-Bannerman C; Biggio JR; Chauhan SP; Hughes BL; Louis JM; Manuck T; Miller HS; Das AF; Birch R; Jozwiakowski MJ
Am J Perinatol; 2018 Oct; 35(12):1228-1234. PubMed ID: 29702708
[TBL] [Abstract][Full Text] [Related]
36. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
37. Should we stop prescribing IM progesterone to women with a history of preterm labor?
Dresang L; Vellardita L
J Fam Pract; 2022 Jan; 71(1):E15-E17. PubMed ID: 35587457
[TBL] [Abstract][Full Text] [Related]
38. Effect of partial compliance on the prevention of recurrent preterm birth in women receiving weekly 17 alpha-hydroxyprogesterone caproate injections.
Haidar ZA; Moussa HN; Hosseini Nasab S; Sibai BM
J Matern Fetal Neonatal Med; 2017 Dec; 30(24):2926-2932. PubMed ID: 27921517
[TBL] [Abstract][Full Text] [Related]
39. Prevention of Preterm Labor with 17α-Hydroxyprogesterone (17OHP) Caproate: A Comparison of Adverse Drug Reaction Rates between Compounded and Commercial Formulations.
Stone RH; Bobowski C; Milikhiker N; Anguiano RH; Mastrogiannis D
Am J Perinatol; 2017 Dec; 34(14):1436-1441. PubMed ID: 28704849
[No Abstract] [Full Text] [Related]
40. Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate.
Manuck TA; Lai Y; Meis PJ; Dombrowski MP; Sibai B; Spong CY; Rouse DJ; Durnwald CP; Caritis SN; Wapner RJ; Mercer BM; Ramin SM
Am J Obstet Gynecol; 2011 Aug; 205(2):135.e1-9. PubMed ID: 21600550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
